These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Emerging targets and therapeutic approaches for the treatment of osteoarthritis pain. Rahman W; Dickenson AH Curr Opin Support Palliat Care; 2015 Jun; 9(2):124-30. PubMed ID: 25730180 [TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study. de Greef BT; Merkies IS; Geerts M; Faber CG; Hoeijmakers JG Trials; 2016 Jun; 17(1):306. PubMed ID: 27363506 [TBL] [Abstract][Full Text] [Related]
30. Challenges in the development of novel treatment strategies for neuropathic pain. Ossipov MH; Porreca F NeuroRx; 2005 Oct; 2(4):650-61. PubMed ID: 16489372 [TBL] [Abstract][Full Text] [Related]
31. The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. Zhou Y; Cai S; Moutal A; Yu J; Gómez K; Madura CL; Shan Z; Pham NYN; Serafini MJ; Dorame A; Scott DD; François-Moutal L; Perez-Miller S; Patek M; Khanna M; Khanna R ACS Chem Neurosci; 2019 Dec; 10(12):4834-4846. PubMed ID: 31697467 [TBL] [Abstract][Full Text] [Related]
32. The first clinical results obtained with a new analgesic--Promalgan. Bănescu O; Dumitrescu C; Mitu S; Dănău M Med Interne; 1982; 20(3):243-4. PubMed ID: 6760367 [No Abstract] [Full Text] [Related]
33. Translational Model Systems for Complex Sodium Channel Pathophysiology in Pain. Schrenk-Siemens K; Rösseler C; Lampert A Handb Exp Pharmacol; 2018; 246():355-369. PubMed ID: 29374838 [TBL] [Abstract][Full Text] [Related]
34. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? Bouhassira D; Attal N Pain; 2018 Mar; 159(3):576-582. PubMed ID: 29447137 [TBL] [Abstract][Full Text] [Related]
35. Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models. Urru M; Muzzi M; Coppi E; Ranieri G; Buonvicino D; Camaioni E; Coppini R; Pugliese AM; Tanaka B; Estacion M; Waxman SG; Dib-Hajj SD; Chiarugi A Pain; 2020 Apr; 161(4):831-841. PubMed ID: 31815915 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Rowbotham MC Neurology; 2005 Dec; 65(12 Suppl 4):S66-73. PubMed ID: 16385106 [TBL] [Abstract][Full Text] [Related]
37. Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm. Taneja A; Della Pasqua O; Danhof M Eur J Clin Pharmacol; 2017 Oct; 73(10):1219-1236. PubMed ID: 28894907 [TBL] [Abstract][Full Text] [Related]
39. Methodological issues associated with clinical trials in neuropathic pain. Gilron I Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1399-1402. PubMed ID: 27659719 [No Abstract] [Full Text] [Related]
40. Synthesis and Evaluation of Novel α-Aminoamides Containing an Indole Moiety for the Treatment of Neuropathic Pain. Li H; Fan S; Cheng J; Zhang P; Zhong B; Shi W Molecules; 2016 Jun; 21(7):. PubMed ID: 27347907 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]